

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 July 2006 (13.07.2006)

PCT

(10) International Publication Number
WO 2006/073366 A1

(51) International Patent Classification:

C07D 275/03 (2006.01) A61K 31/5377 (2006.01)
 A61K 31/425 (2006.01) A61P 25/28 (2006.01)
 A61K 31/427 (2006.01) A61P 3/06 (2006.01)
 A61K 31/4427 (2006.01) A61P 3/10 (2006.01)
 A61K 31/454 (2006.01) A61P 9/00 (2006.01)
 A61K 31/4545 (2006.01) A61P 9/10 (2006.01)
 A61K 31/506 (2006.01) C07D 417/12 (2006.01)

SWANSON, Marianne [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). WEIDOLF, Lars [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). MRICKMANN, Kay [DE/SE]; AstraZeneca, R & D Molndal, SE-431 83 Molndal (SE).

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2006/000029

(22) International Filing Date: 9 January 2006 (09.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0500055-9 10 January 2005 (10.01.2005) SE

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BROO, Anders [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). HOLM, Patrik [FI/FI]; Skärgårdsvägen 984, FIN-21600 Pargas (FI). JUDKINS, Robert [GB/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LI, Lanna [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINDSTEDT-ALSTERMARK, Eva-Lotte [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SANDBERG, Pernilla [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS



(I)

(57) Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

WO 2006/073366 A1